收藏切换
Identifying Adverse Events of Ofatumumab and Rituximab in the Treatment of Multiple Sclerosis Based on the FAERS Database
收藏切换
PDF
Ying LI1, 2, Mingyuan GUAN1, 2, Ranran DUAN3, *, Jian KANG1, 2, *
Chinese Pharmaceutical Journal | 2024, 59(9) : 845 - 851
Less
收藏切换
Chinese Pharmaceutical Journal | 2024, 59(9): 845-851
Identifying Adverse Events of Ofatumumab and Rituximab in the Treatment of Multiple Sclerosis Based on the FAERS Database
Full
Ying LI1, 2, Mingyuan GUAN1, 2, Ranran DUAN3, *, Jian KANG1, 2, *
Affiliations
  • 1 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • 2 Henan Drug Clinical Comprehensive Evaluation Center, Zhengzhou 450052, China
  • 3 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Published: 2024-05-08 doi: 10.11669/cpj.2024.09.011
Outline
收藏切换

OBJECTIVE To investigate adverse event signals associated with ofatumumab and rituximab in the treatment of multiple sclerosis(MS), provide more evidences for the clinical safe medication based on the U.S. food and drug administration's adverse event reporting system(FAERS) data. METHODS Postmarking adverse event reports of ofatumumab and rituximab were extracted to form an analysis dataset. Disproportionality analysis combined with bayesian confidence propagation neural nework (BCPNN) was conducted for adverse event signal monitoring. Adverse events meeting threshold conditions were selected and summarized for analysis. RESULTS The ofatumumab group collected a total of 72 310 adverse event reports, of which 325 showed positive signals, covering 24 system organ classes (SOCs), involving “infections and infestations” “nervous system disorders” and “musculoskeletal and connective tissue disorders”. The rituximab group collected 23 203 adverse event reports, with 311 showing positive signals, covering 25 SOC, involving “injury, poisoning and procedural complications” “infections and infestations” and “nervous system disorders”. Except for “gastrointestinal disorders” and “eye disorders”, both drugs exhibited significant differences in each SOC. CONCLUSION There are substantial differences in the risk of adverse events between ofatumumab and rituximab in the treatment of MS. Therefore, medication monitoring is required during the treatment. Due to the limitations of real-world studies for quantitative analysis, the above conclusions need to be validated through large-scale cohort studies.

ofatumumab  /  rituximab  /  reporting system  /  adverse event  /  multiple sclerosis
Ying LI, Mingyuan GUAN, Ranran DUAN, Jian KANG. Identifying Adverse Events of Ofatumumab and Rituximab in the Treatment of Multiple Sclerosis Based on the FAERS Database[J]. Chinese Pharmaceutical Journal, 2024 , 59 (9) : 845 -851 . DOI: 10.11669/cpj.2024.09.011
Year 2024 volume 59 Issue 9
PDF
176
85
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2024.09.011
  • Receive Date:2023-06-19
  • Online Date:2025-11-25
  • Published:2024-05-08
Article Data
Affiliations
History
  • Received:2023-06-19
Funding
Affiliations
    1 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
    2 Henan Drug Clinical Comprehensive Evaluation Center, Zhengzhou 450052, China
    3 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2024.09.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT